

Acyclic Retinoid Inhibits Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BLKS/J- +Lepr^{db}/+Lepr^{db} Mice

Masahito Shimizu¹, Hiroyasu Sakai¹, Yohei Shirakami¹, Junpei Iwasa¹, Yoichi Yasuda¹, Masaya Kubota¹, Koji Takai¹, Hisashi Tsurumi¹, Takuji Tanaka², and Hisataka Moriwaki¹

Abstract

Obesity and the related metabolic abnormalities are associated with increased risk of hepatocellular carcinoma (HCC). Malfunctioning of retinoid X receptor (RXR) α due to phosphorylation by Ras/MAPK also plays a critical role in liver carcinogenesis. In the present study, we examined the effects of acyclic retinoid (ACR), which targets RXR α , on the development of diethylnitrosamine (DEN)-induced liver tumorigenesis in C57BLKS/J- +Lepr^{db}/+Lepr^{db} (*db/db*) obese mice. Male *db/db* mice were given tap water containing 40 ppm DEN for 2 weeks, after which they were fed a diet containing 0.03% or 0.06% of ACR throughout the experiment. In mice treated with either dose of ACR for 34 weeks, the development of liver cell adenomas was significantly inhibited as compared with basal diet-fed mice. ACR markedly inhibited the activation of Ras and phosphorylation of the ERK (extracellular signal-regulated kinase) and RXR α proteins in the livers of experimental mice. It also increased the expression of RAR β and *p21^{CIP1}* mRNA while decreasing the expression of *cyclin D1*, *c-Fos*, and *c-Jun* mRNA in the liver, thereby restoring RXR α function. Administration of ACR improved liver steatosis and activated the AMPK protein. The serum levels of insulin decreased by ACR treatment, whereas the quantitative insulin sensitivity check index (QUICKI) values increased, indicating improved insulin sensitivity. The serum levels of TNF- α and the expression levels of TNF- α , *IL-6*, and *IL-1 β* mRNA in the livers of DEN-treated *db/db* mice were decreased by ACR treatment, suggesting attenuation of the chronic inflammation induced by excessive fatty deposits. ACR may be, therefore, useful in the chemoprevention of obesity-related HCC. *Cancer Prev Res*; 4(1); 128–36. ©2010 AACR.

Introduction

Hepatocellular carcinoma (HCC) is a serious health-care problem worldwide. The risk factors associated with the development of HCC include chronic hepatitis B and/or hepatitis C infection, particularly with subsequent cirrhosis. Recent evidence also indicates that obesity and the related metabolic abnormalities, especially diabetes mellitus, increase the risk of HCC (1–3). In a rodent model, the occurrence of diethylnitrosamine

(DEN)-induced liver tumorigenesis was found to be significantly higher in obese and diabetic C57BLKS/J- +Lepr^{db}/+Lepr^{db} (*db/db*) mice than in genetic control mice (4). Diabetes mellitus has been shown to increase the risk of primary HCC in patients with viral hepatitis (5). Insulin resistance is also significantly associated with the recurrence of stage I HCC after curative treatment (6). Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of the insulin resistance syndrome, and in a subset of NAFLD patients, the condition progresses to nonalcoholic steatohepatitis, which involves severe inflammation and therefore poses the threat of HCC (7, 8). Coexistent obesity or steatosis exacerbates liver injury and fibrosis and thus is involved in liver tumorigenesis (9). Therefore, patients with obesity and insulin resistance comprise a high-risk group for HCC, and their treatment must target the prevention of this malignancy.

Acyclic retinoid (ACR, the same substance as NIK-333), a synthetic retinoid, apparently exerts chemopreventive effects on the development of HCC (10). It inhibits experimental liver carcinogenesis and suppresses the

Authors' Affiliations: ¹Department of Medicine, Gifu University Graduate School of Medicine, Gifu, Japan, and ²Department of Oncologic Pathology, Kanazawa Medical University, Ishikawa, Japan

Note: Supplementary data for this article are available at Cancer Prevention Research Online (<http://cancerprevres.aacrjournals.org/>).

Corresponding Author: Masahito Shimizu, Department of Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan. Phone: 81-(58)-230-6313; Fax: 81-(58)-230-6310; E-mail: shimim-gif@umin.ac.jp

doi: 10.1158/1940-6207.CAPR-10-0163

©2010 American Association for Cancer Research.

growth of HCC-derived cells by inducing apoptosis and causing cell-cycle arrest in G₀-G₁ (11–15). These effects of ACR are associated with its agonistic activity for distinct nuclear retinoid receptors—retinoid X receptors (RXR) and retinoic acid receptors (RAR), both of which have 3 subtypes (α , β , and γ ; 16)—and subsequent expression of the ACR target genes *RAR β* and *p21^{CIP1}* (12–15). A clinical trial revealed that oral administration of ACR significantly reduced the incidence of posttherapeutic HCC recurrence and improved the survival rates of patients (17, 18). A phase II/III trial of ACR confirmed its effectiveness in preventing second primary HCC in hepatitis C virus–positive patients in a large-scale ($n = 401$) randomized, placebo-controlled trial; hazard ratio for recurrence-free survival with ACR 600 mg/d versus placebo was 0.27 (95% CI, 0.07–0.96) after 2 years randomization (19).

Among the retinoid receptors, RXR α is considered as one of the most important receptors with respect to the regulation of fundamental cell activities because it forms a heterodimer with other nuclear receptors and thereby acts as the master regulator of nuclear receptors (20). Recent studies indicate that phosphorylation of RXR α abolishes its ability to form a heterodimer with RAR β , and the accumulation of phosphorylated RXR α (p-RXR α , i.e., nonfunctional RXR α), which is caused by activation of the Ras/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathway, plays a critical role in the development of HCC (10, 21, 22). On the other hand, the effects of ACR in suppressing growth and inducing apoptosis in HCC cells depend on the inactivation of Ras-ERK signaling system and subsequent RXR α dephosphorylation (15, 23, 24). In the present study, we examined the effects of ACR on obesity-related liver tumorigenesis by focusing on the inhibition of RXR α phosphorylation. We also examined whether ACR treatment improves the insulin resistance, liver steatosis, and inflammatory condition caused by obesity with DEN-treated *db/db* mice, a useful preclinical model, to evaluate the mechanisms underlying the inhibition of obesity-related liver tumorigenesis by chemopreventive drugs (4).

Materials and Methods

Animals and chemicals

Four-week-old male *db/db* mice were obtained from Japan SLC, Inc. All mice received humane care and were housed at Gifu University Life Science Research Center in accordance with the Institutional Animal Care Guidelines. DEN was purchased from Sigma Chemical Co. ACR was supplied by Kowa Pharmaceutical Co.

Experimental procedure

The experimental protocol, which was approved by the Institutional Committee of Animal Experiments of Gifu University, was as described previously (4). At

5 weeks of age, 40 *db/db* mice were randomly divided into 5 groups. All the mice in groups 1 ($n = 10$), 2 ($n = 10$), and 3 ($n = 10$) were given tap water containing 40 ppm of DEN for the first 2 weeks, which is sufficient to develop liver neoplasms in *db/db* mice (4). After DEN treatment, the mice in groups 2 and 3 were fed the basal diet CRF-1 (Oriental Yeast Co.) containing 0.03% ACR (group 2) or 0.06% ACR (group 3), respectively, with free access to the feed till the end of experiment. Group 4 ($n = 5$) was fed the CRF-1 diet containing 0.06% ACR. The mice in groups 1 and 5 ($n = 5$) were fed the CRF-1 diet throughout the experiment. The rationale for the doses (0.03% and 0.06%) selection of ACR was based on previous studies, in which similar doses of ACR inhibited experimental liver carcinogenesis induced by chemical agents (25, 26). At 41 weeks of age (after 34 weeks of ACR treatment), all the mice were sacrificed by CO₂ asphyxiation to check for the development of HCC, liver cell adenoma, and foci of cellular alteration (FCA).

Histopathologic analysis

At sacrifice, the livers were immediately removed and macroscopically inspected for the presence of neoplasms. Maximum sagittal sections of each lobe (6 lobes) were used for histopathologic examination. For all experimental groups, 4- μ m thick sections of formalin-fixed, paraffin-embedded livers were stained routinely with hematoxylin and eosin (H&E) for histopathologic examination. The presence of HCC, liver cell adenoma, and FCA was judged according to previously described criteria (27). The multiplicity of FCA was assessed on a per unit area (cm²) basis.

Ras activation assay

Ras activity was determined using a Ras activation assay kit (Upstate Biotechnology) according to the manufacturer's instructions. Ras was precipitated in equivalent amounts of liver extract (50 μ g) from DEN-treated mice (groups 1–3) by using Raf-1/Ras-binding domain-immobilized agarose, which was then subjected to Western blot analysis using anti-Ras antibody (24). The intensity of the blots was quantified using NIH imaging software Version 1.62.

Protein extraction and Western blot analysis

Total protein was extracted from the nontumor site of livers of DEN-treated mice, and equivalent amounts of proteins (30 μ g per lane) were examined by Western blot analysis (4). Previously described primary antibodies for RXR α (Δ N-197 and D-20), ERK, phosphorylated ERK (p-ERK), Stat3, p-Stat3, AMP-activated kinase (AMPK), p-AMPK, and GAPDH were used (15, 22, 28, 29). The Δ N-197 antibody is considered a specific antibody for the p-RXR α protein (22, 23). The GAPDH antibody served as a loading control.

RNA extraction and quantitative real-time reverse transcription PCR

Total RNA was isolated from the nontumor site livers of DEN-treated mice by using the RNAqueous-4PCR kit (Ambion Applied Biosystems). cDNA was amplified from 0.2 µg of total RNA by using the SuperScript III First-Strand Synthesis System (Invitrogen), and quantitative real-time reverse transcription PCR (RT-PCR) analysis was carried out as described previously (4). The specific primers used for amplification of the *TNF-α*, *IL-6*, *IL-1β*, and *β-actin* genes were as described previously (30). The primers for the amplification of *RARβ*, *p21^{CIP1}*, *cyclin D1*, *c-Jun*, and *c-Fos* genes are listed in Supplementary Table S1.

Clinical chemistry

Before sacrifice, the mice were fasted for 6 hours, and at sacrifice, blood samples were collected for assaying the serum concentrations of insulin, glucose, and *TNF-α*, which was as described previously (4, 29). The serum *TNF-α* (Shibayagi) levels were determined using an enzyme immunoassay according to the manufacturer's protocol. Insulin resistance was estimated by determining the quantitative insulin sensitivity check index (QUICKI) as follows: $QUICKI = 1/[\log(I_0) + \log(G_0)]$, where I_0 is the fasting insulin level and G_0 is the fasting glucose level, which correlates with the glucose clamp method (31).

Hepatic lipid analysis

Approximately 200 mg of frozen liver was homogenized, and lipids were extracted using Folch's method (32). The levels of triglyceride in the liver were measured using the triglyceride E-test kit (Wako Pure Chemical Co.) according to the manufacturer's protocol. To visualize the intrahepatic lipids, Sudan III staining was conducted using the standard procedure with frozen sections.

Statistical analysis

The results are presented as the mean ± SD and were analyzed using the GraphPad InStat software program Version 3.05 (GraphPad Software) for Macintosh. Differences among the groups were analyzed by either 1-way ANOVA or, as required, by 2-way ANOVA. When the ANOVA showed a statistically significant effect ($P < 0.05$), each experimental group was compared with the control group by using the Tukey–Kramer multiple comparisons test. The differences were considered significant when the 2-sided P value was less than 0.05.

Results

General observations

As shown in Table 1, no significant differences were observed in the body, kidney, and fat weights among the groups at the end of the study. A significant decrease in the liver weight was observed in the ACR-treated groups as compared with the basal diet-fed group ($P < 0.05$ or $P < 0.01$), irrespective of DEN treatment. Histopathologic

examination showed the absence of ACR toxicity in the liver, kidney, and spleen (data not shown).

Effects of ACR on DEN-induced liver tumorigenesis in *db/db* mice

Table 2 summarizes the incidence and multiplicity of liver neoplasms (adenoma and HCC) and FCA in the mice from all groups. FCA developed in the livers of mice from all groups, irrespective of DEN treatment. On the other hand, liver cell adenomas developed only in the DEN-treated *db/db* mice. HCCs also developed in all DEN-treated groups; however, the incidence (10% in each group) was not high. These findings might be associated with experimental protocol because the duration of the experiments (41 weeks) was sufficient to develop adenoma but not HCC. In mice treated with either dose (0.03% and 0.06%) of ACR, the incidence ($P < 0.01$ in each comparison) and multiplicity of adenoma ($P < 0.05$ or $P < 0.01$) were significantly inhibited compared to ACR-untreated mice. The number of FCA was also significantly decreased by ACR treatment, irrespective of DEN treatment ($P < 0.001$ or $P < 0.05$).

Effects of ACR on Ras activity and phosphorylation of RXRα, ERK, and Stat3 proteins in the livers of DEN-treated *db/db* mice

ACR prevents the growth of HCC cells by inactivating Ras-ERK and dephosphorylating RXRα, thereby restoring RXRα function (10, 15, 23, 24). Stat3 is also an ACR target for the inhibition of cancer cell growth (28). Therefore, the effects of ACR on the inhibition of Ras activity and phosphorylation of the RXRα, ERK, and Stat3 proteins were examined in this study by using an obesity-related liver tumorigenesis model. As shown in Figure 1A, the activity of Raf-1-bound Ras in the liver was significantly inhibited by treatment with either dose of ACR ($P < 0.01$). The expression levels of the p-ERK and p-RXRα proteins were also decreased by ACR treatment (Fig. 1B), indicating that ACR inhibits the development of obesity-related liver neoplasms, at least in part, by dephosphorylating RXRα and thereby restoring its function. At both doses, ACR also decreased the expression levels of the p-Stat3 protein in the livers of DEN-treated *db/db* mice (Fig. 1B).

Effects of ACR on the expression levels of RARβ, p21^{CIP1}, cyclin D1, c-Fos, and c-Jun mRNA in the livers of DEN-treated *db/db* mice

ACR inhibits the growth of HCC cells by increasing the cellular levels of RARβ and p21^{CIP1} but decreasing the levels of cyclin D1, and these effects might be associated with the restoration of RXRα function (12–15). It also suppresses the growth of cancer cells by inhibiting the activity of AP-1, which comprises the Jun and Fos oncoprotein families (28). Therefore, the effect of ACR on the mRNA levels of these molecules was examined next. As shown in Figure 1C, quantitative real-time RT-PCR analysis indicated that ACR treatment

Table 1. Body, liver, kidney, and fat weights of the experimental mice

Group no.	Treatment	No. of mice	Weight, g			
			Body	Liver	Kidney	Fat ^a
1	DEN alone	10	71.2 ± 8.8 ^b	4.5 ± 0.8	0.9 ± 1.0	7.5 ± 2.2
2	DEN + 0.03% ACR	10	65.7 ± 7.2	3.3 ± 1.1 ^c	0.5 ± 0.1	6.0 ± 1.5
3	DEN + 0.06% ACR	10	66.0 ± 7.4	3.0 ± 0.7 ^d	0.5 ± 0.1	5.7 ± 1.3
4	0.06% ACR alone	5	66.0 ± 7.4	3.0 ± 0.7 ^e	0.5 ± 0.1	5.7 ± 1.3
5	Basal diet	5	67.9 ± 7.8	4.8 ± 1.0	0.6 ± 0.1	6.2 ± 1.4

^aWhite adipose tissue of the periorchis and retroperitoneum.

^bMean ± SD.

^cSignificantly different from group 1 by Tukey–Kramer multiple comparison test ($P < 0.05$).

^dSignificantly different from group 1 by Tukey–Kramer multiple comparison test ($P < 0.01$).

^eSignificantly different from group 5 by Tukey–Kramer multiple comparison test ($P < 0.05$).

significantly increased the expression levels of *RARβ* and *p21^{CIP1}* mRNA, especially *RARβ* mRNA, in the livers of DEN-exposed *db/db* mice ($P < 0.01$). On the other hand, the expression levels of *cyclin D1*, *c-Fos*, and *c-Jun* mRNA were significantly decreased by ACR treatment ($P < 0.01$).

Effects of ACR on hepatic steatosis and the activation of AMPK in the livers of DEN-treated *db/db* mice

Hepatic steatosis is considered a promoter of the development of HCC (8, 9). Therefore, whether ACR treatment enhances the accumulation of lipids in the liver of experimental mice was examined. Examination of Sudan III–stained sections revealed that ACR treatment significantly improved macrovesicular steatosis in the livers of DEN-treated *db/db* mice (Fig. 2A, top panels). The triglyceride levels in the liver were also

significantly decreased in mice treated with ACR at either dose ($P < 0.05$) in comparison with those fed the basal diet (Fig. 2A, bottom graph). Moreover, ACR markedly phosphorylated (activated) the AMPK protein, which is a critical serine/threonine kinase that monitors cellular energy status (33), in the livers of the experimental mice (Fig. 2B).

Effects of ACR on insulin resistance in DEN-treated *db/db* mice

Insulin resistance plays a critical role in the development of HCC (1–6). Therefore, the effects of ACR on the levels of serum insulin and QUICKI values, which indicate the degree of insulin sensitivity, were examined in DEN-treated *db/db* mice. As shown in Figure 2C, the serum insulin level was decreased ($P < 0.05$) whereas the QUICKI value was increased in mice treated with 0.06% ACR ($P < 0.05$).

Table 2. Incidence and multiplicity of hepatic neoplasms and FCA in the experimental mice

Group no.	Treatment	No. of mice	Incidence		Multiplicity ^a		FCA (No./cm ²)
			Adenoma	HCC	Adenoma	HCC	
1	DEN alone	10	7/10 (70%)	1/10 (10%)	1.3 ± 1.2 ^b	0.1 ± 0.3	15.1 ± 3.5 ^c
2	DEN + 0.03% ACR	10	1/10 (10%) ^d	1/10 (10%)	0.2 ± 0.6 ^e	0.1 ± 0.3	6.6 ± 2.5 ^f
3	DEN + 0.06% ACR	10	1/10 (10%) ^d	1/10 (10%)	0.1 ± 0.3 ^g	0.1 ± 0.3	2.8 ± 1.8 ^f
4	0.06% ACR alone	5	0/5 (0%)	0/5 (0%)	0	0	3.0 ± 2.8 ^h
5	Basal diet	5	0/5 (0%)	0/5 (0%)	0	0	8.0 ± 1.2

^aNumber of neoplasms per mouse.

^bMean ± SD.

^cSignificantly different from group 5 by Tukey–Kramer multiple comparison test ($P < 0.001$).

^dSignificantly different from group 1 by Fisher's exact probability test ($P < 0.01$).

^eSignificantly different from group 1 by Tukey–Kramer multiple comparison test ($P < 0.05$).

^fSignificantly different from group 1 by Tukey–Kramer multiple comparison test ($P < 0.001$).

^gSignificantly different from group 1 by Tukey–Kramer multiple comparison test ($P < 0.01$).

^hSignificantly different from group 5 by Tukey–Kramer multiple comparison test ($P < 0.05$).




Figure 1. Effects of ACR on Ras activity; phosphorylation of RXR α , ERK, and Stat3 proteins; and the expression of target genes in the livers of DEN-treated *db/db* mice. The total proteins and mRNAs were extracted from the livers of DEN-treated mice. A, the Ras activities were determined using a Ras activation assay kit (top). The relative intensity of the blots was quantified by densitometry and is displayed in the bottom graph. B, the expression levels of the RXR α , p-RXR α , ERK, p-ERK, Stat3, and p-Stat3 proteins were examined by Western blot analysis, using the respective antibodies. Equal protein loading was verified by the detection of GAPDH. Two lanes represent protein samples from two different mice from each group. Repeat Western blots yielded similar results. C, the expression levels of *RARβ*, *p21^{CIP1}*, *cyclin D1*, *c-Fos*, and *c-Jun* mRNA were examined by quantitative real-time RT-PCR using specific primers. β -Actin was used as a control. Each experiment was performed in triplicate, and the average value was calculated. Values are the mean \pm SD. *, $P < 0.01$ vs. ACR-untreated group.

compared with those in the basal diet-fed group. These findings suggest that ACR improves insulin resistance in obese and diabetic *db/db* mice.

Effects of ACR on the serum levels of TNF- α and hepatic expression of TNF- α , IL-6, and IL-1 β mRNA in DEN-treated *db/db* mice

Because a state of chronic inflammation induced by excessive production of storage lipids and insulin resistance is associated with obesity-related liver carcinogenesis (34), the effects of ACR on the levels of the proinflammatory cytokines TNF- α , IL-6, and IL-1 β in DEN-treated *db/db* mice were examined. As shown in Figure 3A, the serum levels of TNF- α were decreased after ACR treatment ($P < 0.01$). Furthermore, the expression levels of TNF- α , IL-6, and IL-1 β mRNA in the livers of DEN-treated *db/db* mice were also significantly decreased by ACR treatment ($P < 0.01$). The decrease was most apparent in the levels of IL-6 mRNA:

the inhibition rates were about 85% at both doses of ACR (Fig. 3B).

Discussion

In the present health care scenario, the effects of obesity, including the promotion of cancer, are critical issues that need to be resolved and HCC is one of the representative malignancies influenced by excessive body weight and related metabolic abnormalities (1–3, 5, 6). A recent clinical trial revealed that supplementation of food with branched-chain amino acids (BCAA), which improves insulin resistance (35), reduced the risk of HCC in obese patients with chronic viral liver disease (3). BCAA supplementation also suppresses liver tumorigenesis in obese and diabetic *db/db* mice by improving insulin resistance and attenuating liver steatosis and fibrosis (4). The results of the present study clearly indicated that ACR also effectively




Figure 2. Effects of ACR on hepatic steatosis, the activation of the AMPK protein in the liver, and the levels of serum insulin and insulin sensitivity in DEN-treated *db/db* mice. **A**, frozen liver sections from DEN-exposed mice treated with or without ACR were stained with Sudan III to show steatosis (top). Hepatic lipids were extracted from the frozen livers of these mice, and the triglyceride levels were measured (bottom). **B**, the total proteins were extracted from the livers of DEN-treated mice, and the expression levels of the AMPK and p-AMPK proteins were examined by Western blot analysis, using the respective antibodies. A GAPDH antibody served as a loading control. **C**, the serum concentration of insulin was measured by enzyme immunoassay (left). The QUICKI value was calculated to evaluate insulin sensitivity (right). Values are the mean \pm SD. *, $P < 0.05$ vs. ACR-untreated group.

prevents the development of obesity-related liver cell adenomas, and these effects are associated with improvement of hepatic steatosis and insulin resistance. Therefore, the findings of the present study, together with the results of previous studies using BCAA (3, 4), suggest that improvement of metabolic abnormalities by pharmaceutical or nutritional intervention might be an effective strategy for inhibiting obesity-related liver tumorigenesis.

Several biological effects of ACR are relevant to the prevention of obesity-related hepatotumorigenesis. First, it should be noted that ACR inhibits RXR α phosphorylation by suppressing the Ras/ERK signaling pathway in the livers of DEN-treated *db/db* mice. These findings are consistent with those of previous *in vitro* studies (15, 23, 24), but this is the first *in vivo* experiment, and the results seem to be significant because RXR α malfunction due to the phosphorylation by Ras-ERK plays a role in liver carcinogenesis and phosphorylated RXR α is therefore a critical target for HCC chemoprevention (10, 21). ACR suppresses the growth of HCC cells by inhibiting RXR α phosphorylation and restoring its original function as a master regulator

of nuclear receptors (15, 22–24). Therefore, the expression levels of the RAR β , *p21^{CIP1}*, *cyclin D1*, *c-Fos*, and *c-Jun* genes, which are ACR targets (12–15, 28), were notably regulated by treatment with this agent. Among these molecules, RAR β seems to be the most important with respect to the induction of apoptosis (36). The upregulation of *p21^{CIP1}*, which negatively modulates cell-cycle progression, also activates the promoter region of the RAR β gene (37). Because RAR β can form a heterodimer with RXR α and thus synergistically inhibit the growth of HCC cells (14, 15), its induction might also have played a role in preventing the development of liver tumors in the present study. In addition, *p21^{CIP1}* induction, which might be caused by activation of transforming growth factor (TGF)- β , also contributes to prevent the development of liver neoplasms because TGF- β induces senescence and inhibits growth in HCC cells by upregulating *p21^{CIP1}* and ACR can activate latent TGF- β in liver stellate cells (38, 39).

Next, the effects of ACR in improving hepatic steatosis and insulin resistance, both of which accelerate HCC development (7–9), are discussed. These effects might also




Figure 3. Effects of ACR on the serum levels of TNF- α and the expression levels of TNF- α , IL-6, and IL-1 β mRNA in the livers of DEN-treated *db/db* mice. A, the serum concentration of TNF- α was measured by enzyme immunoassay. B, the expression levels of TNF- α , IL-6, and IL-1 β mRNA were examined by quantitative real-time RT-PCR using specific primers. The expression levels of these mRNAs were normalized to the level of the β -actin mRNA. Values are the mean \pm SD. *, $P < 0.01$ vs. ACR-untreated group.

be associated with RXR α dephosphorylation, as RXR can control insulin sensitization and lipid metabolism by forming a heterodimer with peroxisome proliferator-activated receptor (PPAR), an important molecule in the regulation of lipid homeostasis and energy metabolism (40). This speculation is interesting because the inhibition of RXR α phosphorylation and the activation of the RXR/PPAR heterodimer are also activities that cooperatively inhibit the growth of cancer cells (41). In addition, ACR might improve these metabolic abnormalities by activating AMPK, which increases glucose uptake and fatty acid oxidation but decreases fatty acid synthesis (33). This is another positive finding with regard to the prevention of hepatotumorigenesis because decreased AMPK activation is implicated in tumor development and therefore may be a promising target for cancer chemoprevention (42, 43). For instance, a human study suggests that metformin, an AMPK activator used to treat type 2 diabetes mellitus, reduces the cancer risk in diabetic patients (44). Dietary energy restriction suppresses mammary tumorigenesis in rats by increasing the levels of activated AMPK (45). Pitavastatin, a lipophilic statin, was found to prevent obesity- and diabetes-related colon carcinogenesis in mice by activating AMPK in the colonic mucosa (29). These reports suggest the possibility that activation of AMPK by ACR aided in suppressing the development of obesity-related liver cells adenomas, as observed in the present study.

Insulin resistance and lipid accumulation in the liver produce inflammatory changes in the liver (7–9). ACR might decrease the serum levels of TNF- α and the expres-

sion levels of TNF- α , IL-6, and IL-1 β mRNA in the livers of experimental mice by improving hepatic steatosis and insulin resistance. These findings are significant because obesity-related HCC development clearly depends on enhanced production of TNF- α and IL-6, which cause hepatic inflammation and activate ERK and Stat3 (34). TNF- α , which lies at the core of the association between obesity and insulin resistance (46), contributes to obesity-induced IL-6 production and hepatocarcinogenesis (34). IL-6 is a major Stat3 activator in the liver, and the activation of the IL-6–Stat3 axis plays a critical role in HCC development (47, 48). In addition, uncontrolled activation of the Ras/ERK and Jak/Stat pathways is essential for HCC development (49). In the present study, ubiquitous activation of Ras-ERK signaling presumably caused accumulation of the p-RXR α protein in the liver of the obese mice. Our findings indicate that the effects of ACR in improving the inflammatory response and inhibiting Ras-ERK and Stat3 activation are crucial to prevent the development of obesity-related liver tumors.

Finally, it should be emphasized again that prevention of HCC by targeting hepatic steatosis, insulin resistance, and the state of chronic inflammation, which are caused by dysregulation of energy homeostasis, might be one of the promising strategies for the treatment of obese individuals who are at an increased risk of developing HCC (3, 4). ACR seems to be potentially effective and critical candidate for this purpose because it can improve hepatic steatosis and insulin resistance while also attenuating chronic inflammation. It inhibits RXR α phosphorylation induced by

Ras-ERK activation, which might be associated with excess adipose tissue, and this effect is also important for preventing obesity-related liver tumorigenesis. The findings of the present study, together with the results of previous clinical trials indicating that ACR can significantly prevent the development of HCC in patients with viral cirrhosis without causing serious adverse effects (17–19), encourage the clinical usage of this agent for cirrhotic patients with obesity and diabetes. On the other hand, careful observation is required to apply a retinoid in clinical practice because of its potential toxicity. For instance, ACR may worsen hypertriglyceridemia in obese and diabetic subjects, which is a side effect observed in previous clinical trial (17), limiting the application of ACR to such subjects.

References

1. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004;126:460–8.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007;132:2557–76.
3. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. *Hepatology* 2006;35:204–14.
4. Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y, et al. Dietary supplementation with branched-chain amino acids suppresses diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. *Cancer Sci* 2010;101:460–7.
5. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. *Am J Gastroenterol* 2001;96:2462–7.
6. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, et al. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: a prospective, case series study. *Hepatology* 2010;40:376–82.
7. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. *Cancer* 2009;115:5651–61.
8. Smedile A, Bugianesi E. Steatosis and hepatocellular carcinoma risk. *Eur Rev Med Pharmacol Sci* 2005;9:291–3.
9. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. *Hepatology* 2005;42:5–13.
10. Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. *Cancer Sci* 2009;100:369–74.
11. Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. *J Natl Cancer Inst* 1984;73:1389–93.
12. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1. *Cancer Res* 2002;62:3997–4006.
13. Suzui M, Shimizu M, Masuda M, Lim JT, Yoshimi N, Weinstein IB. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. *Mol Cancer Ther* 2004;3:309–16.
14. Shimizu M, Suzui M, Deguchi A, Lim JT, Xiao D, Hayes JH, et al. Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma cells. *Clin Cancer Res* 2004;10:6710–21.
15. Tatebe H, Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Tsurumi H, et al. Acyclic retinoid synergises with valproic acid to inhibit

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported in part by grants-in-aid from the Ministry of Education, Science, Sports and Culture of Japan (no. 22790638 to M. Shimizu and no. 21590838 to H. Moriwaki) and by grant-in-aid for the 3rd Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 16, 2010; revised September 2, 2010; accepted October 19, 2010; published OnlineFirst November 11, 2010.

- growth in human hepatocellular carcinoma cells. *Cancer Lett* 2009;285:210–7.
16. Araki H, Shidoji Y, Yamada Y, Moriwaki H, Muto Y. Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. *Biochem Biophys Res Commun* 1995;209:66–72.
 17. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al. Prevention of second primary tumors by an acyclic retinoid, polyphenolic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. *N Engl J Med* 1996;334:1561–7.
 18. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. *N Engl J Med* 1999;340:1046–7.
 19. Okita K, Matsui O, Kumada H, Tanaka K, Kaneko S, Moriwaki H, et al. Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial. *J Clin Oncol* 2010;28Suppl 7s:4024.
 20. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. *Pharmacol Rev* 2006;58:760–72.
 21. Matsushima-Nishiwaki R, Okuno M, Adachi S, Sano T, Akita K, Moriwaki H, et al. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. *Cancer Res* 2001;61:7675–82.
 22. Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, et al. Phosphorylated retinoid X receptor alpha loses its heterodimeric activity with retinoic acid receptor beta. *Cancer Sci* 2007;98:1868–74.
 23. Matsushima-Nishiwaki R, Okuno M, Takano Y, Kojima S, Friedman SL, Moriwaki H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. *Carcinogenesis* 2003;24:1353–9.
 24. Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, et al. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells. *Cancer Sci* 2007;98:431–7.
 25. Kagawa M, Sano T, Ishibashi N, Hashimoto M, Okuno M, Moriwaki H, et al. An acyclic retinoid, NIK-333, inhibits N-diethylnitrosamine-induced rat hepatocarcinogenesis through suppression of TGF-alpha expression and cell proliferation. *Carcinogenesis* 2004;25:979–85.
 26. Sano T, Kagawa M, Okuno M, Ishibashi N, Hashimoto M, Yamamoto M, et al. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. *Nutr Cancer* 2005;51:197–206.
 27. Frith CH, Ward JM, Turusov VS. Tumours of the liver. In: Turusov VS, Mohr U, editors. *Pathology of Tumors in Laboratory Animals*. Vol 2. Lyon, France: IARC Scientific Publications; 1994. p. 223–70.

28. Shimizu M, Suzui M, Deguchi A, Lim JT, Weinstein IB. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. *Clin Cancer Res* 2004;10:1130–40.
29. Yasuda Y, Shimizu M, Shirakami Y, Sakai H, Kubota M, Hata K, et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. *Cancer Sci* 2010;101:555–66.
30. Sakai H, Yamada Y, Shimizu M, Saito K, Moriwaki H, Hara A. Genetic ablation of TNFalpha demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis. *Chem Biol Interact* 2010;184:423–30.
31. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000;85:2402–10.
32. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. *J Biol Chem* 1957;226:497–509.
33. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nat Rev Mol Cell Biol* 2007;8:774–85.
34. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell* 2010;140:197–208.
35. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. *Int J Mol Med* 2008;22:105–12.
36. Alvarez S, Germain P, Alvarez R, Rodriguez-Barrios F, Gronemeyer H, de Lera AR. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. *Int J Biochem Cell Biol* 2007;39:1406–15.
37. Teraishi F, Kadowaki Y, Tango Y, Kawashima T, Umeoka T, Kagawa S, et al. Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment. *Int J Cancer* 2003;103:833–9.
38. Senturk S, Mumcuoglu M, GURSOY-Yuzugullu O, Cingoz B, Akcali KC, Ozturk M. Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. *Hepatology* 2010;52:966–74.
39. Okuno M, Moriwaki H, Imai S, Muto Y, Kawada N, Suzuki Y, et al. Retinoids exacerbate rat liver fibrosis by inducing the activation of latent TGF-beta in liver stellate cells. *Hepatology* 1997;26:913–21.
40. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. *Nature* 1997;386:407–10.
41. Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, et al. Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells – phosphorylated RXR alpha is a critical target for colon cancer management. *Gut* 2007;56:1557–63.
42. Fay JR, Steele V, Crowell JA. Energy homeostasis and cancer prevention: the AMP-activated protein kinase. *Cancer Prev Res* 2009;2:301–9.
43. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. *Biochim Biophys Acta* 2010;1804:581–91.
44. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. *BMJ* 2005;330:1304–5.
45. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. *Cancer Res* 2008;68:5492–9.
46. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. *Science* 1996;271:665–8.
47. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science* 2007;317:121–4.
48. He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. *Cancer Cell* 2010;17:286–97.
49. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. *Gastroenterology* 2006;130:1117–28.